← Leaderboards
Gaddiel Galarza-Munoz
Autoimmunity Biologic Solutions, Inc.
$2,713,934
Attributed
$2,713,934
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2019–23$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,713,934 · 6
By mechanism
R42$1,403,826 · 1
R43$801,441 · 3
R41$508,667 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Autoimmune Diseases”
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
- Gary Fanger · Rise Therapeutics, Llc$13,503,380
- Florence Burleson · Brt-Burleson Research Technologies, Inc.$10,161,265
- Raghuveera Yaramolu · Eminent Services Corporation$9,791,923
- Paul John Norman · University Of Colorado Denver$8,123,209
- Seyed Ahmad Sajjadi · University Of California-Irvine$7,854,983
Research focus
Autoimmune DiseasesPharmaceutical PreparationsExclusionInterleukin 7 ReceptorAntisense OligonucleotidesRna SplicingT-LymphocyteMediatingIn VivoExonsExperimental Autoimmune EncephalomyelitisImmune SystemImmunologicsRheumatoid ArthritisSystemic Lupus ErythematosusLeadMouse ModelInsulin-Dependent Diabetes MellitusMultiple SclerosisAutoimmune ProcessAlternative SplicingFutureIn VitroEtiology
Grant awards (7)
Development of a novel accurate therapy for multiple sclerosis$403,826
R42 · FY2023 · AI · contact PI
Development of a novel accurate therapy for multiple sclerosis$1,000,000
R42 · FY2022 · AI · contact PI
Strategy for specific delivery of antisense oligonucleotides to T cells$306,500
R43 · FY2022 · AI · contact PI
Development of antisense oligonucleotides that enhance sIL7R as novel cancer immunotherapy$324,675
R43 · FY2021 · CA · contact PI
Determination of optimal antisense oligonucleotide chemistry for efficient and safe splicing modulation in T cells$283,667
R41 · FY2020 · AI · contact PI
Development of a novel accurate therapy for Multiple Sclerosis$225,000
R41 · FY2019 · AI · contact PI
Novel accurate therapy for Multiple Sclerosis: Optimization of antisense oligonucleotides delivery and functionality in primary T cells$170,266
R43 · FY2019 · AI · contact PI